The past five years have been one of the more challenging periods for raising capital in the biotechnology industry, especially for early-stage companies.
Numerous factors, including a challenging FDA environment upon NDA submission, long timelines to approval and the high rate of drug failure, have contributed to a skeptical venture capitalist view of the sector’s prospects. As a result, emerging growth biotechnology companies are increasingly pursuing alternative financing vehicles, including Equity Crowdfunding, to advance their drug development programs.
What is Crowdfunding?
Crowdfunding is a joint effort by individuals to support a cause, company or organization by pooling their resources, usually via the Internet. These individuals are collectively referred to as the "crowd." Industries that have popularized crowdfunding in recent years include software, gaming, media/film, and the music industry.
Please click on the link below to download the White Paper, "How Equity Crowdfunding Can Help Life Science Companies."
http://sjordanassociates.com/how-equity-crowdfunding-can-help-life-science-companies/